Clinical study of the effectiveness of edaravone for the oxidative stress in amyotrophic lateral sclerosis

Clinical study of the effectiveness of edaravone for the oxidative stress in amyotrophic lateral sclerosis - Clinical study for the anti-oxidative stress by edaravone in ALS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024854

Enrollment

Registered

2016-11-16

Start date

2016-11-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

Edaravone treatment for ALS patients

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ALS patients diagnosed as ALS definite, ALS probable, or probable ALS laboratory supported in EI Escorial arranged Airie House diagnosis criteria, with disease duration within 3 years

Exclusion criteria

Exclusion criteria: Severe renal dysfunction (Cr > 3.0 mg/dl) and impossible evaluations for motor functions

Design outcomes

Primary

Measure	Time frame
We evaluate the effects of edaravone for oxidative stress, anti-oxidative stress and vascular endothelial function in ALS patients.	—

Countries

Japan

Contacts

Public ContactYasuyuki Ohta

Okayama university Department of Neurology

yasuyuki@okayama-u.ac.jp086-235-7365

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026